MYIA
AIMT

Mount Yale Investment Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Mount Yale Investment Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-834
Closed -$27K – 893
2018
Q3 		$27K Buy
834
+248
+42% +$7.01K ﹤0.01% 726
2018
Q2 		$16K Buy
+586
New +$17.9K ﹤0.01% 837

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Mount Yale Investment Advisors's AIMT Position: Q4 2018 in Review

Mount Yale Investment Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2018, closing a stake of 834 shares — an estimated $27K sold.

Mount Yale Investment Advisors first reported a position in AIMT in Q2 2018 and held it in 2 quarters. The position peaked at $27K in Q3 2018. 132 funds tracked by Wall St. Rank hold AIMT as of Q4 2018.

  • Mount Yale Investment Advisors reported no remaining Aimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 834 Aimmune Therapeutics shares in Q4 2018, an estimated $27K.
  • Mount Yale Investment Advisors first reported a position in Aimmune Therapeutics in Q2 2018 and held it in 2 quarters.
  • Mount Yale Investment Advisors's Aimmune Therapeutics position peaked at $27K in Q3 2018.
  • 132 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2018.

Based on Mount Yale Investment Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.